TG Therapeutics is a commercial-stage biopharmaceutical company focused on B-cell mediated diseases, best known for BRIUMVI (ublituximab), an anti-CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis. It develops and commercializes therapies aimed at autoimmune and oncology indications linked to B-cell biology. Differentiation rests on its antibody-based franchise and a concentrated MS commercial footprint rather than a broad primary-care portfolio.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 141.2 | — | 28.2 | — |
| Q3 2025 | 161.7 | — | 390.9 | — |
| Q4 2025 | 192.6 | — | 23 | — |
| Q1 2026 | 204.9 | — | 19.8 | — |
| Q2 2026 | 240.3 | 70.3% | 7.8 | -72.4% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: InterDigital, Inc. (IDCC), Axsome Therapeutics, Inc. (AXSM), Viavi Solutions Inc. (VIAV), FormFactor, Inc. (FORM), Viasat, Inc. (VSAT), Columbia Banking System, Inc. (COLB)